Skip to main
ACHV

ACHV Stock Forecast & Price Target

ACHV Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Achieve Life Sciences is a financially sound company with a strong focus on research and development, as evidenced by the successful completion of a Phase 2 study for its lead product. The company also has a potentially valuable market segment for vaping cessation, which could provide a significant revenue stream. With experienced leadership and a promising product in the pipeline, Achieve Life Sciences has the potential for long-term success and growth in the pharmaceutical industry.

Bears say

Achieve Life Sciences is heavily dependent on the success and approval of cytisinicline, with a projected peak penetration in its initial target population of only 12% leading to net U.S. sales of ~$800 million, and the company's financials are heavily reliant on this drug's success. The company is also facing competition in the smoking cessation market, and any potential regulatory delays or lower than expected adoption rates could negatively impact the company's financial performance. Additionally, there have been concerns raised about the potential for nausea side effects with cytisinicline, which could limit patient compliance and affect the drug's sales and overall success in the market.

ACHV has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Achieve Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Achieve Life Sciences (ACHV) Forecast

Analysts have given ACHV a Strong Buy based on their latest research and market trends.

According to 3 analysts, ACHV has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Achieve Life Sciences (ACHV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.